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Abstract 
Background: More than 50 years after the discovery of antibiotics, bacterial infections have decreased substantially; 
however, antibiotics also may have negative effects such as increasing susceptibility to pathogens. An intact micro-
biome is an important line of defense against pathogens. We sought to determine the effect of orally administered 
antibiotics both on susceptibility to pathogens and on impact to the microbiome. We studied Campylobacter jejuni, 
one of the most common causes of human diarrhea, and Acinetobacter baumannii, which causes wound infections. 
We examined the effects of antibiotic treatment on the susceptibility of mice to those pathogens as well as their influ-
ence on the mouse gut microbiome.
Results: In C57/BL6 mice models, we explored the effects of pathogen challenge, and antibiotic treatment on the 
intestinal microbiota. Mice were treated with either ciprofloxacin, penicillin, or water (control) for a 5-day period fol-
lowed by a 5-day washout period prior to oral challenge with C. jejuni or A. baumannii to assess antibiotic effects on 
colonization susceptibility. Mice were successfully colonized with C. jejuni more than 118 days, but only transiently 
with A. baumannii. These challenges did not lead to any major effects on the composition of the gut microbiota. 
Although antibiotic pre-treatment did not modify pathogen colonization, it affected richness and community struc-
ture of the gut microbiome. However, the antibiotic dysbiosis was significantly reduced by pathogen challenge.
Conclusions: We conclude that despite gut microbiota disturbance, susceptibility to gut colonization by these path-
ogens was unchanged. The major gut microbiome disturbance produced by antibiotic treatment may be reduced by 
colonization with specific microbial taxa.
Keywords: Microbiome, Antibiotic treatment, Pathogen challenge, Penicillin, Ciprofloxacin, Campylobacter jejuni, 
Acinetobacter baumannii, High-throughput sequencing, Next-generation sequencing
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Background
The mammalian intestine hosts a complex and diverse 
microbial community [1, 2]. This ecosystem interacts 
extensively with its host, with substantial physiological 
and pathological effects [3]. For example, the gut micro-
biota is crucial to the host’s ability to resist colonization 
by pathogens [4, 5], although the mechanisms involved 
are incompletely characterized [6].
The clinical use of antibiotics has become massive in 
recent decades [7]. Their use increases susceptibility 
to acquired pathogen, although the underlying mecha-
nisms are not well-understood [8]. Antibiotics change the 
composition of microbiota in the GI tract [9], affecting 
metabolic, hormonal, and immunological interactions 
between community and host, as well as intra-commu-
nity interactions [10–12]. Separately, or together, these 
effects may increase host susceptibility to infection by 
introduced pathogens.
Campylobacter jejuni are Gram-negative, microaero-
philic, curved rods, that commonly cause diarrheal 
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illnesses, and can affect previously healthy hosts [13–15]. 
Acinetobacter baumannii, non-fermentative Gram-
negative cocobacilli, have become increasingly common 
nosocomial pathogens, especially in intensive care units 
(ICUs) [16, 17]. The high prevalence of intestinal A. bau-
mannii colonization in ICU patients suggests that the 
colon may be an important reservoir [18].
In this study, we developed mouse models involving 
colonization with these human pathogens to address 
three questions germane to colonization resistance; (1) 
what is the extent to which pathogens such as C. jejuni 
or A. baumannii colonize the GI tract of mice; (2) how 
does such colonization affect the gut microbiota; and (3) 
does pre-treatment with antibiotics change microbiota 
compositions and affect susceptibility to colonization by 
these pathogens?
Methods
Study design
Three related experiments were conducted in which con-
trol (untreated) mice were compared to experimental 
mice that were challenged by a pathogen, either alone, or 
in conjunction with antibiotic pre-treatment. In experi-
ment #1, 7 week-old mice were challenged with either A. 
baumannii or C. jejuni (Additional file 1: Figure S1, panel 
A). In experiment #2, 6  week-old mice were challenged 
with one of three strains of C. jejuni that varied based on 
their mouse-passage histories (Additional file  1: Figure 
S1, panel B). In experiment #3, mice were exposed first to 
an antibiotic regime of either penicillin or ciprofloxacin 
or neither (control), and then were challenged with either 
A. baumannii or C. jejuni, or remained unchallenged 
(Additional file 1: Figure S2).
Mice
Female C57BL/6NJ mice were obtained from Jack-
son Laboratories at ~5 to 6 weeks of age and allowed to 
adjust to the NYU animal facility for 1 week. The animals 
then were used in experiment #1 (Additional file 1: Fig-
ure S1, panel A). In addition, animals originally received 
from Jackson Laboratories were used for breeding at 
the NYU animal facility, and the offspring females were 
used for experiments #2 and 3 (Additional file 1: Figure 
S1, panel B). In experiment #3, 10 days prior to bacterial 
challenge, mice were given water containing penicillin 
VK (0.167  mg/ml; Sigma Aldrich, St Louis MO, USA), 
or ciprofloxacin (0.13 mg/ml; Acros Organics, Geel, Bel-
gium), or no antibiotic (control) for 5  days. Water con-
tainers were changed twice during these 5 days to supply 
fresh antibiotics. The protocols for the mouse experi-
ments included in this study were approved by the New 
York University School of Medicine Institutional Animal 
Care and Use Committee (IACUC).
Bacterial strains used for mice inoculation
Campylobacter jejuni strain 81-176, that was originally 
isolated from a milkborne outbreak of human campylo-
bacteriosis [19], and has been used in human volunteer 
studies [20], was used in all three experiments. For experi-
ment #2, we used two additional C. jejuni strains that 
were recovered from mice experimentally inoculated with 
strain 81-176 in experiment #1. Campylobacter jejuni 
strain MP-10 was isolated from mouse stool 42 days after 
colonization, and C. jejuni strain Cecum J1 was isolated 
from the cecum of a mouse 119  days after colonization. 
All C. jejuni strains were cultured for 48  h on Skirrow 
agar (Becton–Dickinson, Franklin Lakes NJ, USA) under 
microaerobic conditions at 37  °C. Cultures then were 
resuspended in phosphate-buffered saline (PBS; pH 7.2) 
and adjusted to a concentration of 108 CFU (by OD600) in 
400 µl, which was introduced via oral gavage to test mice. 
Control mice received an oral gavage of 400 µl of PBS.
Acinetobacter baumannii strain 11-1, used in experi-
ments #1 and 3, was a recent clinical isolate obtained 
from the New York University Langone Medical Center 
(NYULMC) Clinical Microbiology Laboratory. Acineto-
bacter baumannii was cultured for 24 h using Columbia 
sheep blood agar (BD) and CHROM agar Acinetobacter 
Base (DRG International, Springfield NJ, USA) under 
aerobic conditions at 37  °C. Acinetobacter baumannii 
was resuspended in PBS and adjusted to a concentration 
of 1.3 × 1011 CFU (by OD600) per 400 µl to create the oral 
gavage inoculum.
Fecal specimen collection, culture and DNA extraction
In all experiments, fecal specimens were collected from 
mice before and after pathogen challenge (Additional 
file  1: Figures S1, S2), and were either immediately cul-
tured or frozen at −20  °C. About 20  mg of feces were 
resuspended in 1 ml of PBS and vortex-mixed for 30 s at 
room temperature. From this stock suspension, tenfold 
dilutions were made in PBS. Aliquots (100 µl) of the 100, 
10−2, and 10−3 dilutions were plated on CHROM agar for 
A. baumannii and on Skirrow agar for C. jejuni. Plates 
were incubated under the conditions indicated above 
and colony counts were reported as CFU/mg stool. Fecal 
DNA also was extracted from a 20 mg aliquot of mouse 
feces using the PowerSoil DNA Isolation Kit (MOBIO, 
West Carlsbad CA, USA), according to the manufac-
turer’s protocol. The concentration of extracted DNA 
was determined by Nanodrop 1000 (Thermo Scientific, 
Watham MA, USA), and DNA was stored at −20 °C until 
used.
Quantitative PCR
Sets of qPCR primers (Table 1) were used to quantitate 
bacterial populations, based on the universal bacterial 
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16S rRNA sequences [21], C. jejuni luxS [22], and A. bau-
mannii oxa51 [23]. qPCRs were performed using 3.5 mM 
MgCl2, 0.4 ng/µl bovine serum albumin, 0.2 mM of each 
deoxynucleoside triphosphate, 10  pmol of each primer, 
0.625 U Taq DNA polymerase (Qiagen, Valencia CA, 
USA), and 2  µl extracted DNA in a final 20-µl volume 
of SYBR green master mix. qPCR conditions included 
5 min at 94 °C and 45 cycles of 10 s at 94 °C, 10 s at 60 °C 
(C. jejuni and A. baumannii) or 56 °C (total bacteria). All 
assays were performed using a Light Cycler 480 (Roche 
Diagnostic Corporation, Indianapolis IN, USA). Bacterial 
numbers were determined using standard curves based 
on serial dilutions of cloned PCR products. Each sample 
was tested at least twice, and the results were analyzed 
using the Rotor-Gene 3000 v.6.1.81 software.
Library preparation for high‑throughput sequencing (HTS)
All samples were amplified and barcoded for multiplex 
pyrosequencing using primers targeted to the V4 region 
of the bacterial 16S rRNA gene under uniform PCR con-
ditions that included 3 min at 94 °C and 45 cycles of 45 s 
at 94 °C, 60 s at 50 °C, and 90 s at 72 °C with final exten-
sion for 10  min at 72  °C [24]. We used forward primer 
(AAT GAT ACG GCG ACC ACC GAG ATC TAC ACT 
ATG GTA ATT GTG TGC CAG CMG CCG CGG TAA) 
that includes a 5′ Illumina adaptor, forward primer pad, 
2 bp linker and the 515F 16S rRNA primer, and reverse 
primer (CAA GCA GAA GAC GGC ATA CGA GAT 
NNNNNNNNNNNN—AGT CAG TCA G-CC-GGA 
CTA CHV GGG TWT CTA AT) that includes the Illu-
mina 3′ adapter with 12-nt error-correcting Golay bar-
code, reverse primer pad, 2 bp linker and the 806R 16S 
rRNA primer. We ran PCR in triplicate using 0.2 µM of 
the primers, 1  µl of template and 1X HotMasterMix (5 
PRIME, Gaithersburg MD, USA), and cleaned the prod-
ucts using a PCR Purification Kit (Qiagen) after pool-
ing. Cleaned PCR products were quantified using the 
Qubit dsDNA HS Assay Kit (Invitrogen™, Eugene OR, 
USA), then adjusted to an optimal molarity as described. 
Sequencing was performed using the Illumina MiSeq 
platform in the NYULMC Genome Technology Core.
Taxonomic and ecological analyses
We analyzed all sequence data using the QIIME soft-
ware (version Mac Qiime 1.8.0) [25]. After filtering 
procedures, similar sequences were clustered into opera-
tional taxonomic units (OTUs) using an open reference 
approach with UCLUST [26] against the Greengenes 
Core set. A representative sequence was then aligned 
using PyNAST, and FastTree created phylogenetic trees. 
Rarefaction analysis used Chao-1 and whole PD to meas-
ure α-diversity. Unweighted UniFrac distances were 
calculated to assess β-diversity; the Unweighted paired 
group method with arithmetic mean (UPGMA) was per-
formed for UniFrac-based jackknifed hierarchical clus-
tering. Principal coordinates analysis (PCoA) of UniFrac 
distance matrices provided graphical representation 
using a KiNG, ANOVA was used to compare OTU and 
genus-level abundances, and Linear discriminant analysis 
(LDA) effect size (LEfSe), a tool that can compare differ-
ences of relative abundance between ≥2 biological condi-
tions [27], also was used for analysis.
Results
Quantifying bacteria in fecal DNA
Assessing total DNA concentrations using Nanodrop and 
total bacterial log10 copy number/ng DNA by qPCR, we 
found that they were similar between the control animals 
and those treated with either after antibiotic or pathogen 
challenge (Additional file 1: Figure S3, panels a–j). Thus, 
neither the antibiotic treatments nor the pathogen chal-
lenge affected the overall population size of the intestinal 
microbiota.
Assessment of mouse intestinal colonization 
after challenge
Although we were able to colonize mice with A. bauman-
nii (Fig. 1, left column), as evaluated by both culture and 
qPCR, colonization was transient and at low density. In 
contrast, we could achieve persistent mouse coloniza-
tion with C. jejuni strain 81-176 (for ≥15 weeks), as con-
firmed by both culture and qPCR, until the experiment 
ended (Fig.  1, middle and right columns). Thus, the A. 
baumannii and C. jejuni strains used differed greatly in 
their ability to colonize the murine gut.
Assessment of gut microbiome changes associated  
with C. jejuni challenge and cage effects
We then assessed the gut microbiota in mice followed 
prospectively from 6.5 to 23.9 weeks (Fig. 2). In the ini-
tial pre-challenge samples, the bacterial communities 
were nearly identical in their community structure (col-
umn A). However, over time, the communities differenti-
ated, based on the cage in which they were housed, and 
independently based on C. jejuni challenge or not. Next, 
Table 1 Primers used for PCR in this study
a V = A + C + G, K = G + T, R = A + G
Target Primer designation Primer sequencea
Total bacteria
16S rRNA
519F GGACTACCVGGTATCTAAKCC
785R CAGCAGCCGCGGTRATA
C. jejuni
luxS
F AGCGATCAAAGCAAAATTCC
R GGCAATTTGTTTGGCTTCAT
A. baumannii
Oxa-51
F TTTAGCTCGTCGTATTGGACTTGA
R GCCTCTTGCTGAGGAGTAATTTTT
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assessing the species richness of the gut microbiota, all 
three cages were similar, although at the final time point, 
the C. jejuni-challenged group showed lower richness 
than controls (column B). All three groups were simi-
lar in relative abundance at the genus level (column C) 
except for late changes in S24-7 abundance in cage 2.
Quantitative differences in specific taxa
We next analyzed the HTS results using LEfSe, identi-
fying specific taxa that showed significant differences 
between mice at the beginning (6.5 weeks of life) and end 
(23.9 weeks) of the experiment (Additional file 1: Figure 
S4). Multiple taxa within Firmicutes, Bacilli, and Teneri-
cutes were significantly increased at the early time point 
in the three groups of mice with only cage-related minor 
variations. In contrast, taxa within Bacteroides and Ver-
rucomicrobia were significantly higher at the later time 
point in all groups. Animals in cage 2 showed signifi-
cantly increased Proteobacteria, consistent with our find-
ing of persistent C. jejuni colonization. Proteobacteria 
were not increased in cage 1 (control) as expected, nor 
in cage 3 after C. jejuni colonization had spontaneously 
ceased.
Detection of C. jejuni after mouse passage
Next, we investigated whether three C. jejuni strains with 
different passage histories varied in their abilities to colo-
nize the mouse gastrointestinal tract after oral challenge 
(Additional file  1: Figure S5). All three C. jejuni strains 
showed similar kinetics; culture (panel A) and qPCR 
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Fig. 1 Quantitation of A. baumannii and C. jejuni intestinal colonization. Upper panels Detection by culture. Lower panels Detection by qPCR. Quanti-
tation of A. baumannii is shown for weeks 7–8.5. Quantitation of C. jejuni is shown for weeks 7–12, and for weeks 7–26
(See figure on next page.) 
Fig. 2 Assessment of change in gut microbiome following C. jejuni challenge. Mice were challenged with either PBS (cage 1), or C. jejuni (cages 
2 and 3) at 7 weeks of age. Fecal pellets were collected serially, DNA extracted, and HTS performed on the Illumina Miseq platform. β-diversity 
(column A) α-diversity (column B). and relative taxon abundance at the genus level (color-coded, column C) are shown. Light blue indicates control 
group (cage 1); dark blue indicates C. jejuni group (cage 2); red indicates another C. jejuni group (cage 3)
Page 5 of 10Iizumi et al. Gut Pathog  (2016) 8:60 
0
20
40
60
Seq / sample
R
ef
ra
ct
io
n 
M
ea
su
re
 w
ho
le
 P
D
0
20
40
60
Seq / sample
R
ef
ra
ct
io
n 
M
ea
su
re
 w
ho
le
 P
D
0
20
40
60
Seq / sample
R
ef
ra
ct
io
n 
M
ea
su
re
 w
ho
le
 P
D
0
20
40
60
Seq / sample
R
ef
ra
ct
io
n 
M
ea
su
re
 w
ho
le
 P
D
C. jejuni challenge 
week
Cage 2 (C. jejuni)
Cage 3 (C. jejuni)
Cage 1 (control)
6.5
8.3
10.5
15.0
19.9
23.9
PC2 (6.5%) 
a b c
PC3 (5%) 
PC1 (12%) 
0
20
40
60
Seq / sample
R
ef
ra
ct
io
n 
M
ea
su
re
 w
ho
le
 P
D
***
***
0
20
40
60
Seq / sample
R
ef
ra
ct
io
n 
M
ea
su
re
 w
ho
le
 P
D ***
C
ag
e 
1
C
ag
e 
2
C
ag
e 
3
Akkermansia
S24-7 
Oscillospira
Clostridiaceae
Allobaculum
Lactobacillus 
Clostridiales Rikenellaceae
Bacteroides
Page 6 of 10Iizumi et al. Gut Pathog  (2016) 8:60 
results (panel B) were consistent. Despite some variations 
in the kinetics of colonization, all three C. jejuni strains 
colonized the mouse gut to similar degrees.
Effect of antibiotic treatment on mouse intestinal 
colonization
We next studied the effect of pre-treatment of the mice 
with penicillin or ciprofloxacin, two antibiotics often 
used in clinical practice, on gut colonization with C. 
jejuni or A. baumannii. The antibiotics used to pre-treat 
the mice had no significant influence on intestinal colo-
nization with either pathogen (Fig.  3). As in previous 
experiments, A. baumannii only transiently colonized 
the mice.
Assessment of gut microbiota changes associated 
with bacterial challenge and antibiotic pre‑treatment
We assessed the gut microbiome in mice followed for 
nearly 9  weeks. Assessment of β-diversity of the gut 
microbiota in the group of mice with no antibiotic 
treatment had nearly identical community structure at 
6 different time points, indicating stable populations. 
However, mice treated with penicillin showed dramatic 
changes in β-diversity, across time. In contrast, mice 
treated with ciprofloxacin had minor effects in β-diversity 
(Fig. 4, panel A).
We next performed analysis of β-diversity of the 
gut microbiota in relation to antibiotic treatment and 
pathogen challenge. As before, mice with no antibiotic 
treatment had nearly identical community structure, 
regardless of pathogen challenge. In the group of mice 
receiving ciprofloxacin, the no challenge group had 
minor changes in β-diversity compared to either the A. 
baumannii or C. jejuni challenged groups. As above, mice 
treated with penicillin showed dramatic changes in com-
munity structure. However, mice treated with penicillin 
and challenged with C. jejuni changed in β-diversity and 
then recovered immediately. Similar but less dramatic 
effects were observed in mice treated with penicillin and 
challenged with A. baumannii (Fig. 4, panel B).
A.
C.
a b c d
e f g h
Fig. 3 Quantitation of A. baumannii and C. jejuni in fecal pellets. a, e Culture detection. b–d, f–h qPCR assessment. Mice received 5 days of PBS (b, 
f), ciprofloxacin (c, g), or penicillin (d, h) and then were pathogen-challenged. The blue box indicates the period of antibiotic exposure. The yellow 
arrow indicates inoculation date of challenge with either A. baumannii (a–d) or C. jejuni (e–h)
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Analysis of longitudinal inter‑group phylogenic distances 
associated with bacterial challenge and antibiotic 
treatment
We observed minor β-diversity differences of the gut 
microbiota in the different mouse groups at time 1 
(4.3  week) which was before antibiotic treatment and 
pathogen challenge. As such, we considered that the 
difference may be related to cage effects at that time 
point (Additional file  1: Figure S6, panel A). Next, we 
analyzed the intergroup variability at different time 
points in relation to antibiotic treatment and pathogen 
challenge, using the PERMANOVA metric. We did not 
observe significant differences in community structure 
in the mice challenged with either A. baumannii or C. 
jejuni without antibiotic pre-treatment (control groups) 
at any time point. In contrast, community structure in 
the mice treated with antibiotics and challenged with A. 
baumannii were significantly different from community 
structure before challenge. Furthermore, community 
structure of antibiotic-treated mice that were chal-
lenged with C. jejuni also were significantly different 
than pre-challenge (Data not shown). The community 
structure differences in the mice treated with penicillin 
and challenged with C. jejuni were significantly greater 
than before challenge (Additional file  1: Figure S7). 
Interestingly, these data suggest that the presence of C. 
jejuni minimized microbiome susceptibility to penicillin 
effects.
In mice without antibiotic pre-treatment, α-diversity 
was highest in the C. jejuni-challenged group; due to the 
short follow-up of the A. baumannii group, we could not 
assess changes. We consistently observed that in ani-
mals treated with penicillin, α-diversity was significantly 
increased in those challenged with C. jejuni; ciprofloxa-
cin did not affect richness (Additional file  1: Figure S6, 
panel B).
Finally, the relative abundance of taxa in the control 
mice (not pre-treated with antibiotics), that were chal-
lenged with A. baumannii or C. jejuni (Fig. 5, column A) 
differed little from the (control) mice without challenge. 
There was a major effect on taxa abundances in mice pre-
treated with penicillin, but this was significantly reduced 
after A. baumannii, or C. jejuni challenge (column C). In 
contrast, ciprofloxacin had much smaller effects (Fig.  5, 
column B).
Discussion
In these studies, persistent colonization was achieved 
with C. jejuni, an intestinal pathogen, but not with A. 
baumannii, consistent with prior reports [28, 29]. We 
assessed the health status of the mice challenged with the 
pathogens and with or without antibiotic treatment and 
we did not notice any significant change in behavior or 
signs of disturbances in the health of mice that confirmed 
previous information that mice do not express disease 
after colonization with C. jejuni [30, 31].
Longitudinal assessment of bacterial gut community 
structure indicates that at early time points, essentially all 
mice were identical at the phylum level. However, as the 
experiments progressed, community structures varied, 
due to cage effects, and independently in relation to anti-
biotic treatment, or C. jejuni challenge.
However, the community richness in the gut microbi-
ome was relatively constant, unaffected by cage, or anti-
biotic effects. Nevertheless, C. jejuni challenge increased 
richness, which was affected by penicillin pre-treatment. 
Mouse-adapted strains of C. jejuni were not better than a 
parental strain in mouse gut colonization. One hypoth-
esis for the mechanism for the increased richness is that 
C. jejuni competes with dominant strains, permitting the 
more minor taxa to bloom. An alternative hypothesis 
is that C. jejuni infection stimulates production of anti-
microbial peptides, as has been reported [32], and these 
select against the dominant taxa.
Antibiotic pre-treatment showed no effect on the capa-
bilities of C. jejuni and A. baumannii to colonize the 
mice, which for A. baumannii was only transient. We 
recognized that variation in antibiotic concentration 
may cause different effects. However, in this study we 
used antibiotics equivalent of therapeutic doses used in 
humans to reach maximum antibiotic concentration in 
mice. Stable community structure was observed in mice 
for nearly 10  weeks whether challenged or not. Cipro-
floxacin induced minor community-wide disturbances 
but penicillin induced major disturbances (Fig. 5).
In the absence of antibiotic pre-treatment, pathogen 
introduction did not affect relative abundances of the 
colonizing taxa either at the phyla (Fig. 5) or genus level 
(Data not shown). In contrast, antibiotic pre-treatment 
with ciprofloxacin produced minor disturbance of the gut 
microbiota when compare to penicillin. One explanation 
(See figure on previous page.) 
Fig. 4 Assessment of antibiotic effects on intestinal microbial community structure (β-diversity). PCoA of the Unweighted UniFrac distances of 
microbial 16S rRNA sequences (V4 region) in fecal samples at six time points is shown. Colored dots indicate composites of the microbial community 
at 4.3 weeks (blue; before antibiotic treatment), 5.4 weeks (red; current antibiotic treatment), 6.1 weeks (orange), 7.6 weeks (purple), 10.1 weeks (light 
blue), or 13.0 weeks (green), respectively. a PCoA analysis sorted by antibiotic treatment, b each column indicates the antibiotic treatment group, and 
each row represents the bacterial challenge
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may be the lower activity of ciprofloxacin against anaer-
obes [33], in contrast to the known anti anaerobic activ-
ity of penicillin [34, 35]. Surprisingly, the introduction of 
A. baumannii or C. jejuni ameliorated the disturbances 
in the community structure, and facilitated the recov-
ery to normality. We speculate that pathogen introduc-
tion affected either host responses that led to stereotypic 
changes, or to altered competition dynamics in the gut, 
favoring the status quo ante.
In conclusion, the susceptibility to gut colonization by A. 
baumannii and C. jejuni did not change despite the disrup-
tion of the gut microbiota of mice treated with antibiotics. 
The distruption of the gut mictobiota may be reduced by 
C. jejuni colonization but the mechanism is still unknown.
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